 COPENHAGEN, Denmark, April 20, 2021 GLOBE NEWSWIRE -- Evaxion Biotech AS Nasdaq: EVAX Evaxion or the Company, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today a presentation by Jens Kringelum, PhD, Evaxions Director in Genomic Immuno-Oncology, at the 4th Neoantigen Summit Europe, being held virtually April 20-22, focusing on AI in personalized cancer medicine. The presentation described Evaxions recent improvement in determining cancer neoepitopes through measurement and prediction of peptide-MHC pMHC complex stability. 